Clinical trial
Menorrhagia Study in Women With Treatment-resistant Menorrhagia
NCT00288691 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00288691 |
|---|---|
| Title | Menorrhagia Study in Women With Treatment-resistant Menorrhagia |
| Official title | A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Effects of Different Doses of SH T 00127B in Women With Treatment-resistant Menorrhagia Aged 30 to 55 Years After Daily Oral Administration of Multiple Doses for 35 up to 50 Days |
| Lead sponsor | Bayer, Industry |
| Collaborators | TAP Pharmaceutical Products Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Menorrhagia |
| Intervention type | Drug |
| Interventions | Asoprisnil (BAY86-5294), Placebo |
| Enrollment | 26 |
| Start date | Nov 1, 2001 |
| Completion | Jan 1, 2004 |
| First posted | Feb 8, 2006 |
| Last update posted | Dec 30, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: